Subject:
- Active Substance: Empagliflozin
- Name: Jardiance®
- Therapeutic area: Chronic heart failure
- Pharmaceutical company: Boehringer Ingelheim Pharma GmbH & Co. KG
Time table:
- Start: 15.07.2021
- Final decision by G-BA: 06.01.2022
Final decision:
- Hint for a minor additional benefit